Navigation Links
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie. 

The lawsuit alleges that after European patent 1,379,224 was granted to Synergy but prior to issuance, Ironwood and Dr. Currie opposed the patent before the European Patent Office and presented to the European Patent Office and the United States Patent and Trademark Office, data and arguments that were false, contradictory, inaccurate and misleading.  In its complaint, Synergy accuses Ironwood and Dr. Currie of, among other things, unfair competition, fraud and unjust enrichment and seeks $500 million in actual and punitive damages.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in patients to treat chronic idiopathic constipation (CIC) patients. In October 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide in CIC patients. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel disease
'/>"/>

SOURCE Synergy Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc.
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... that power our laptops and electric vehicles could store ... with the help of a sponge-like silicon material. ... graphite traditionally used in one of the battery,s electrodes, ... storage capacity of graphite. A paper describing the material,s ... in Nature Communications . , "Silicon has long ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
(Date:7/10/2014)... will see the two universities and NPL collaborate to ... and industry and their complementary academic strengths., Working with ... shape the scientific priorities of the UK. The establishment ... 300 high-calibre PhD students, will provide a pipeline of ... potential of the Laboratory will be grown through the ...
Breaking Biology Technology:New strategy could uncover genes at the root of psychiatric illnesses 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
(Date:7/11/2014)... set a "mouse TRAP" to capture the early signs ... published in the Journal of Clinical Investigation . ... TRAP to extract cellular and genetic information from a ... the Rockefeller Institute for Medical Research in 2008, TRAP ... or ribosomes, of the cell type of interest. Scientists ...
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... The standard explanation for what causes Alzheimer,s is known ... from of an accumulation of the peptide amyloid beta, the ... the sticky plaques that have defined Alzheimer,s for more than ... spent yearly targeting this toxic peptide but what if ...
... host a conference celebrating the 200th anniversary of ... of Species and the 50th anniversary of the ... Thursday, Oct. 29 to Saturday, Oct. 31. ... History of Science, Darwin/Chicago 2009 will feature presentations ...
... Birmingham (UAB) researchers exploring strategies for conserving the Diamondback ... keep the once-celebrated turtle off the endangered species list. ... a source of state taxes and a casualty of ... its prospects are improved by a UAB-based turtle hatchery ...
Cached Biology News:Rethinking Alzheimer's disease and its treatment targets 2Rethinking Alzheimer's disease and its treatment targets 3UAB research team saves turtle species on the brink 2UAB research team saves turtle species on the brink 3
... The CHEMICON® CaspaTag™ Pan-Caspase In Situ ... detection of active caspases in cells undergoing ... only. Not for use in diagnostic or ... Assay Kits use a novel approach to ...
... nM is available for in vivo ... in: Z. Hassani, G.-F. Lemkine, P. Erbacher, ... B.-A. Demeneix. Lipid-mediated siRNA delivery down regulates ... at picomolar levels. J. Gene Med., 2005, ...
... transfection reagent that achieves over 90 % ... a wide variety of adherent and primary ... siRNA concentrations avoids unwanted toxic and off-target ... higher concentrations, thereby allowing accurate and reliable ...
... Immunoperoxidase Secondary Detection System uses biotin-avidin-HRP complexed ... in the Primary Antibody. The primary antibody ... specimen. Any excess antibody is removed by ... to biotin) is added and will react ...
Biology Products: